• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    Comprehensiv...

    • Clinical research
      • Interdisciplinary pediatric study center (Hauner iPSC)
      • Ped-COVID-19 Study
      • Michael Albert
      • Scivias Study
      • TRACE Study
      • ImmGenDC Study
      • Hematology/Oncology/Coagulation
    • Research Labs
      • Binder Lab
      • Bohlen Lab
      • Braun Lab
      • Gaertner Lab
      • Griese Lab
      • Hauck Lab
      • Hübner Lab
      • Jeremias lab
      • Kim-Hellmuth Lab
      • Klein Lab
      • Koletzko Lab
      • Kotlarz Lab
      • Lange-Sperandio Lab
      • von Mutius Lab
      • Nußbaum Lab
      • Rosenecker Lab
      • Schaub Lab
      • Schmid Lab
      • Schwerd Lab
    • PhD Program
    • Technology platforms
      • Bioinformatics
      • Flow Cytometry
      • High throughput sequencing
      • Microscopy
      • Pre-GMP Facility
      • Mass spectrometry
      • Hauner Biobank
      • Organoid Lab
      • Humangenetik am Hauner
    • News/Events
      • News
      • Rare Disease Day
      • ECHO-Meeting
      • Meinhard von Pfaundler-Lectures
      • Klaus Betke Symposium
    • Join us!
    1. CCRC-HaunerEN
    2. Technology platforms
    3. Pre-GMP Facility

    Pre-GMP Facility

    Bridge to Translation - Immunotherapy from Bench to Bed side

    Cellular immunotherapy requires the set-up of GMP-compatible procedures. The transfer of experimental methods to clinical scale cell engineering includes

    • Automation and up-scale of cell product manufacturing
    • Set-up and validation of quality control
    • Product characterization
    • Pre-clinical data finalization for Clinical Trial Submission
    Cell Product Manufacturing

    For clinical scale cell engineering in a functionally closed system we chose the "CliniMACS Prodigy" device. It offers a platform for GMP-grade cell processing applications enabling fully automated washing, fractionation, cultivation, transduction and magnetic seperation of cells in a functionally closed system.

    The platform´s flexibility allows production of a wide range of cell products under S2 conditions. Further, automation within this device allows harmonization of cell-production processes in case of multicentric production strategies in clinical studies.

    With the electroporator "GTx" (MaxCyte) we also have a GMP-compatible platform for the production of CRISPR/Cas-engineered cell therapy products, which can be combined with our existing platform via a tube system. The new range of non-viral "genetic engineering" processes enables the development of a wide variety of innovative T-cell therapy approaches.

    Set-up of the GMP-conform manufacturing process includes generation of SOP, selection of GMP-compatible reagents and up-scale of lab protocols. Pre-validation runs are performed in order to establish the manufacturing process, train staff and prepare production approval.

    Quality Control

    "MACSQuant Analyzer" offers a GCP-compatible high-throughput platform for flow-cytometry-based quality control. With a range of automated features, this flow cytometer lays the foundation for standardization of analysis and gating procedures. 

    • Absolute quantification of cell populations allows dosing of cell products
    • Automation allows harmonization and standardization of quality control analyses in case of multicentric production 
    • Development of MACSQuant "Express Modes" offers fast and easy quality control analyses

    Quality control strategies are set-up and validated in accordance to the requirements of regulatory authorities.

    Product Characterization

    According to regulatory requirements cell products are pre-clinically characterized using established validation processes and infrastructures:

    • Specificity
    • Purity
    • Potency
    • Identity

    Standardly, stability assays are perfomed in order to determine the shelf-life of the cell products. 

    Staff

    Dr. Theresa Kaeuferle

    Head of Pre-GMP Facility

    Executive Management

    ✉ Theresa.Kaeuferle@med.uni-muenchen.de

    ☎ 089-4400-52338

    Dr. Ramona Krauß

    Regulatory Affairs, Ethics and Biobanking

    ✉ Ramona.Krauss@med.uni-muenche.de

    ☎ 089-4400-52759

    Christina Dietzer

    Quality Management

    ✉ Christina.Dietzer@med.uni-muenchen.de

    ☎ 089-4400-52883


    Teresa Augustin

    Administration

    ✉ Teresa.Augustin@med.uni-muenchen.de

    ☎ 089-4400-54817

    Nadine Stoll

    Technician

    ✉ Nadine.Stoll@med.uni-muenchen.de

    ☎ 089-4400-57790

    Prof. Tobias Feuchtinger

    Dr. von Hauner Children´s Hospital

    Head of Haematology/Oncology Department

    ✉ Kinderkrebszentrum@med.uni-muenchen.de

    ☎ 089-4400-52759

    Mira Reger

    Clinical Trial Management

    ✉ Mira.Reger@med.uni-muenchen.de

    ☎ 089-4400-54816

    Lena Jablonowski

    Doctoral Researcher (PhD track) 

    ✉ Lenamaria.Jablonowski@med.uni-muenchen.de

    ☎ 089-4400-57791

    Maximilian Zwermann

    Doctoral Researcher (MD track) 

    ✉ Maximilian.Zwermann@med.uni-muenchen.de

    ☎ 089-4400-57790

    Patents and Publications

    - 2 Patent Applications

    - Kaeuferle T et al. Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells. Clin. Transl. Immunol. 2022 Jan 11:e1372. doi: 10.1002/cti2.1372

    - Stief TA, Kaeuferle T, Müller TR et al. Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021 May 28:S1525-0016(21)00303-8. doi: 10.1016/j.ymthe.2021.05.021

    - Kaeuferle T et al. CRISPR-Cas9-Mediated Glucocortioid Resistance in Virus-Specific T cells for Adoptive T Cell Therapy Posttransplantation. Mol Ther. 2020 Jun 11:S1525-0016(20)30292-6. doi: 10.1016/j.ymthe.2020.06.002.

    - Kaeuferle T et al. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019 Feb 6:12(1):13. doi: 10.1186/s13045-019-0701-1

    Links
    • Research Lab AG Feuchtinger
    • TRACE - a multinational Phase III T-cell Therapy Study
    • Follow TRACE on LinkedIn

    Contact:

    Dr. Theresa Käuferle

    Head of Pre-GMP Facility

    Dr. von Hauner Children´s Hospital

    Dep. of Haematology/Oncology

    Tel.: 089/4400-52338

    E-Mail: Theresa.Kaeuferle@med.uni-muenchen.de

    Research at CCRC Hauner

    Contact LMU Klinikum

    Contact CCRC Hauner

    Haunersches

    CCRC Hauner - Comprehensive Childhood Research Center

    Kinderklinik und Kinderpoliklinik

    im Dr. von Haunerschen Kinderspital

    Ludwig Maximilians Universität München

    Lindwurmstr. 4

    80337 Munich, Germany


    Editor login
    Imprint | Data-Safety